Effect of Add-on L-Arginine Therapy on Heart Failure Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT07394270

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07394270
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07394270. Randomized; quadruple masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Add-on L-Arginine Therapy on Heart Failure Patients
Condition
Heart Failure
Intervention (Drug)
L-Arginine Powder
Intervention (Drug)
Placebo
Lead sponsor
German University in Cairo (class: other)
Collaborator
Ain Shams University (class: other)

Record details

Record id
cardio:ct-nct07394270
Content hash
27cee607cc54abb9d624d33e78a4dcbb3ac6cc867e41227eb9fb71bb52185041